Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageVericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $76.5MThe company’s own SEC segment disclosure.
- MACI Implants And Kits$65.5M86%
- Epicel$10.4M14%
- Biopsy Kits$614.0K1%
Vericel Corporation (VCEL) reported revenue of $68M in Q1 2026 (quarter ended Mar 31, 2026), up 30% from the same quarter a year earlier. That came with a gross margin of 72% and net loss of $6.3M. For the full year FY2025, revenue was $276M (+16% year on year) and net income $17M. Its largest product in Jun 2026 was MACI Implants And Kits at $66M, 86% of the disclosed total, well ahead of Epicel at 14%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.